8月6日，科伦博泰生物盘中上涨3.4%，报509.0港元，成交额8215.75万港元。
消息面上，公司8月5日公告将于8月17日召开董事会审议中期业绩，市场对业绩兑现预期升温。近期公司管线进展密集：核心产品TROP2 ADC芦康沙妥珠单抗第六项适应症上市申请获NMPA受理并纳入优先审评；合作方默沙东启动sac-TMT联合PD-1/VEGF双抗的II期临床研究；新型双载荷ADC药物SKB565获IND批准。此前高盛、摩根大通分别上调目标价至582.95港元及648港元，维持买入评级。多重催化叠加中报窗口临近，推动资金关注度提升。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.